Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but Not Glucose Parameters

Cells
doi 10.3390/cells8030252
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Treating Hepatitis B Virus/Hepatitis C Virus Coinfected Patients With Direct-Acting Hepatitis C Virus Antivirals Only Is Not Safe

Hepatology
MedicineHepatology
2016English

The Interplay Between Direct-Acting Antivirals and Hepatocellular Carcinoma in Chronic Hepatitis C

Hepatoma Research
2020English

Hepatitis C Related Hepatocellular Carcinoma in the Era of Direct-Acting Antivirals

Hepatoma Research
2018English

Direct‐Acting Antivirals in Hepatitis C Virus‐Associated Diffuse Large B‐cell Lymphomas

Oncologist
Cancer ResearchMedicineOncology
2018English

Ribavirin Steady-State Plasma Level Is a Predictor of Sustained Virological Response in Hepatitis C-Infected Patients Treated With Direct-Acting Antivirals

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Editorial: Ribavirin Continues to Play a Role in Treatment With Direct-Acting Antivirals for Hepatitis C Virus-Infected Patients With Decompensated Cirrhosis

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Hepatitis B Reactivation in Chronic Hepatitis C Patients Treated With Interferon or Pan-Oral Direct-Acting Antivirals

Hepatology
MedicineHepatology
2017English

High Efficacy of Generic and Brand Direct Acting Antivirals in Treatment of Chronic Hepatitis C.

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2018English

Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives

The Scientific World Journal
BiochemistryMedicineGeneticsMolecular BiologyEnvironmental Science
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy